

412 Rec'd PCT/PTO 16 AUG 2001

FORM PTO-1390

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NUMBER
BKS-0002TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (if known see 37 C.F.R. 1.5)

09/913629

INTERNATIONAL APPLICATION NO.
PCT/EP00/01334INTERNATIONAL FILING DATE
18 February 2000PRIORITY DATE CLAIMED
19 February 1999

TITLE OF INVENTION AGENTS FOR CLEANING AND DISINFECTING SURFACES

APPLICANT(S) FOR DO/EO/US Henning SCHUMACHER

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) 35 U.S.C. 371(c)(4).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
- ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
 - A copy of the Published PCT Application by WIPO under WO 00/49118, including the Search Report and references cited.
 - A copy of the International Preliminary Examination Report.

EXPRESS MAIL Mailing Label No. EL 922205558 US

Date of Deposit: August 16, 2001


I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

MAILER Justin Laskowski

SIGNATURE *Justin Laskowski*

EL 922205558US

518 Rev'd OCT/PTO 16 AUG 2001

U.S. APPLICATION NO. (If known 37 CFR 1.5) 09/913629	INTERNATIONAL APPLICATION NO. PCT/EP00/01334	ATTORNEY DOCKET NUMBER BKS-0002
17. The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... \$1,000.00 International preliminary examination fee (37 CFR 1.482 not paid to USPTO but International Search Report has been prepared by the EPO or JPO..... \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$710.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$690.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$100.00		CALCULATIONS PTO USE ONLY
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$860.00
Surcharge of \$130.00 for furnishing the oath or declaration later than _ 20 _ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$
Claims	Number Filed	Number Extra
Total claims	- 20 =	X \$18.00
Independent Claims	- 3 =	x \$80.00
Multiple dependent claims(s) (if applicable)		+ \$270.00
TOTAL OF ABOVE CALCULATIONS =		\$860.00
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		\$430.00
SUBTOTAL =		\$430.00
Processing fee of \$130.00 for furnishing the English translation later than _ 20 _ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		+ \$
TOTAL NATIONAL FEE =		\$430.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property		+
TOTAL FEES ENCLOSED =		\$430.00
		Amount to be: refunded \$
		charged \$
a. <input checked="" type="checkbox"/> A check in the amount of \$ 430.00 to cover the above fee is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 23-3050 in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-3050. A duplicate copy of this sheet is enclosed.		
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.		
SEND ALL CORRESPONDENCE TO: David A. Cherry Woodcock Washburn Kurtz Mackiewicz & Norris LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 (215) 568-3100		
 SIGNATURE		David A. Cherry NAME
35,099 REGISTRATION NUMBER		

Applicant: Dr. Schumacher, Henning
Our file: 80166

Agents for disinfecting and cleaning surfaces

5 The present invention relates to agents for disinfecting and cleaning surfaces, wherein an invert soap having at least one branched alkyl chain, is utilized. In particular, the invention pertains to agents for disinfecting and cleaning surfaces, wherein the invert soap utilized has two short-chain alkyl groups and two long-chain alkyl groups.

10 Surfaces are constantly contaminated with micro-organisms due to exposure to the environment. The presence of such micro-organisms on floors or other surfaces is not desired in particular areas, such as e.g. sanitations, hospitals or swimming pools, or may even be partially hazardous, since there is a danger of an infection and a transmission of germs, respectively, to persons present there. Consequently, such surfaces are treated with disinfectants, which are added to a conventional detergent, which is used for cleaning surfaces. A disadvantage of the
15 known disinfectants resides in that even though a variety of bacteria are killed, but however the efficacy towards viruses is often inadequate.

 The requirements for decontamination of surfaces of medical devices, such as dental suction devices, endoscopes or other hollow bodies, which are introduced into living organisms during surgery are even higher. Therefore, these devices have to be cleaned from contaminating
20 material, such as body fluids, e.g. blood or secretory fluid, each time when used. In order to prevent a transmission of pathogenic micro-organisms, such as bacteria, funghi and/or viruses to patients, treated subsequently, these agents have to be removed, killed or at least inactivated.

 During the last few years specific processing devices, such as specific "washing machines" for endoscopes, have been utilized for cleansing and disinfecting such devices, so as
25 to avoid a direct contact of the devices with the personnel during the entire process.

 These apparatuses are run in a two step process at ambient temperature. In a first step the devices charged thereto are subjected to a treatment with known detergents, such as anionic or non-ionic surfactants and enzymes, respectively, to degrade biological contaminations. In a second step they are contacted with disinfectants on the basis of aldehydes.

30 However, it has been shown that the time required for cleansing and decontaminating the

devices by these apparatuses took too long, in order to have a cleaned and disinfected device available during clinical tests whenever required. In addition, the devices could have been contaminated with germs present in the water utilized for rinsing, which the germs could have multiplied during inappropriate storage of the devices and therefore could render it infectious for a patient.

Due to these problems, the two-step process for cleaning and decontaminating medical devices is run at elevated temperatures up to 60 °C maximum. To this end, the goods charged are introduced into a washing department within the apparatus, the temperature of the cleansing bath is raised and, during step one, a detergent is dosed into the cleansing bath at a particular temperature. After finalizing the cleaning step, the cleansing bath is discharged and in a second step fresh water supplemented with a disinfectant is added such that after a certain processing time period at a chosen temperature the devices should be free of pathogenic agents and should be degerminated. After discharging the apparatus the devices are rinsed with water once or twice, whereupon the devices are ready to use them again.

The agents used for this type of processing are variants of the products used for the processing at ambient temperature.

Normally, combinations of non-ionic surfactants together with complexing agents and enzymes are used as cleansing agents. All of those cleansing agents strive to improve the moistening of the devices' hydrophobic surfaces and thus to increase the volume of the water that passes through the occasionally existing narrow or confined lumina of such devices during processing.

The disinfectants utilized in this process are all based on aldehydes. Aldehydes are of low corrosive nature and enable inactivation of a variety of micro-organisms. However, the efficacy of aldehydes towards spores is extremely low.

Even though particular viruses, such as picorna-viruses, as well as myco-bacteria may be inactivated simply by choosing temperatures of up to 60 °C during the known processes, an inactivation of other viruses, such as Hepatitis B viruses, is not sufficiently possible by applying the presently known disinfecting methods.

Further, the known processes suffer from the disadvantage that the aldehydes utilized fix blood or proteins that had not been entirely removed during the first cleansing step onto the surface of the devices. Thus, it has been found that such a fixation often occurs on the surfaces of the confined lumina so that the residual contamination is not noticed upon an unspecific visual

5

10

15

20

25

30

patients is minimized.

Moreover, the disinfectants of the present invention may generally be applied for the disinfective cleansing of all types of surfaces, such as floors, in particular floors of hospitals or swimming pools, or for combating fungal infection on the skin, such as athlete's foot, due to the
5 tolerance of the skin. Thus, the health risk of the personnel or the person using the agent may be minimized.

The disinfectants of the present invention may be used in the processing apparatuses commonly put to use or even in open containers at temperatures of from ambient temperature to about 75 °C. Having a view to the medical device to be handled treating temperatures of from
10 about 40°C to 65°C or about 50°C to 60°C are preferred.

During a processing of devices using the agents of the present invention sterilized water is introduced into the processing apparatus if necessary, optionally after a pre-cleansing step. In order to improve the efficacy of the process a disinfectant may be used during the pre-cleansing step, which needs, however, not to be identical to the agent of the present invention.

15 The water utilized during processing may have any hardness, which does not negatively affect the efficacy of the agents of the present invention. Having a view to the formation of a deposit onto the devices or in the apparatus it is possible to adapt the recipe of the applied agents of the present invention such that a calcification does not occur. The agents suitable for this purpose are well known to the skilled person. The use of desalted water may likewise be
20 envisaged.

The agent of the present invention is dosed into the cold or already heated processing bath, which may be effected manually or by means of a automatic control system. Depending on the situation of the apparatus put to use and based on his common technical skill the skilled person will decide on the appropriate dosage of the agent of the present invention to be utilized
25 as well as adapt the temperature accordingly and determine, whether the temperature of the bath shall be raised immediately after dosing or whether it shall be maintained for a predetermined period of time.

In carrying out the process for processing medical devices it is preferred that the temperature of the bath is raised to the temperature for disinfecting without changing the bath,
30 while maintaining it by agitation of the water and cleansing and by disinfecting the devices for a particular period of time. After discharging the cleansing and disinfecting bath the device is then rinsed with clear and preferably conditioned water, i.e. water having a reduced number of germs

or being essentially aseptic, so as to be ready for further use. A subsequent drying of the medical device after rinsing may be effected without being necessary.

The specific conduct of the process of the present invention is determined by the assembly of the processing apparatus used and by the type of devices to be processed. In theory a
5 processing at elevated temperature of the processing bath may also be performed manually.

For disinfecting and cleaning of surfaces, such as floors, the agent may simply be added to the washing fluid, wherein the agent will enable a high cleaning and degerminating activity. It has been shown that the agent of the present invention is well accepted by the skin and does not tend to foam.

10 The agent of the present invention contains an invert soap, which has at least one branched alkyl group having 4 to 20 carbon atoms. The branchings may be at any position of the alkyl chain and comprise methyl, ethyl, propyl or butyl branches, respectively, on the main chain. In addition, more than only one branching may also be present, such as e.g. two or more of
15 methyl, ethyl or propyl branches or mixtures thereof, wherein the branches may be present on the same or on different carbon atoms on the main chain. In particular preferred branched chains comprise C₈-C₁₂-alkyl groups, that contain methyl and/or ethyl branches. A most preferred example of a branched alkyl group is isononyl, which may be obtained from LONZA under the product name "Bardac 2170".

The other residues of the positively charged nitrogen atom may be branched or also linear
20 alkyl groups containing from 1 to about 20 carbon atoms, e.g. methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl and dodecaacyl groups. In addition aryl groups and aralkyl groups, respectively, such as benzyl or phenyl groups, or oxyalkyl groups may be bound to the nitrogen atom.

25 Invert soaps are preferred, wherein the branched but also the linear alkyl groups contain independently of from 4 to 20 carbon atoms, preferably between 6 to 16, particularly preferred between 8 and 14, more particularly preferred between 8 and 12 carbon atoms. A combination of branched and linear C₈-C₁₂-alkyl chains has been shown to be particularly effective. The alkyl groups may be unsaturated, with saturated alkyl groups being preferred.

30 According to a preferred embodiment the invert soaps comprise two long-chain alkyl groups each with more than 4 carbon atoms, with at least one of them being branched, and two short-chain alkyl groups each with 1 to 3 carbon atoms, i.e. methyl, ethyl and/or propyl. The

long-chain and short-chain, respectively, alkyl groups on the nitrogen atom may be identical or different, with the proviso that at least one branched alkyl group is bound to the nitrogen atom.

The synthesis of such invert soaps is known in the art and may be carried out by any person skilled in the field of organic chemistry.

5 As the counter-ions anorganic ions may be used, such as fluoride, chloride, bromide or iodide, as well as organic anions, such as e.g. citrate, propionate and ethyl sulfate or methyl sulfate, respectively. During processing the ion is considered as the counter-ion that is present during application of the agent of the present invention in a large excess or alone and affects the properties of the product and not the ion that saturates the positive charge of the nitrogen atom
10 upon addition of the microbicide agent. However, on the basis of his own technical knowledge and by considering the circumstances and objectives the skilled person will use the appropriate counter-ion.

 The invert soap is solved in a solvent to improve application, e.g. water, with additional surfactants, anti-corrosive agents, foam-reducing agents, acids and bases, respectively, for
15 adjusting the desired pH, colourants and/or fragrances may be present as well.

 Apart from using the above mentioned invert soaps the additional use of other, commonly known microbicide substances is likewise possible, such as e.g. aldehydes, in particular glutaraldehyde, benzalkoniumchloride, didecylmethyloxethylammonium propionate, polyhexamethylene biguanide and its salts, chlorhexidine and its salts, chlorine and chlorine generating
20 agents, such as chloramine T, and/or per-compounds, such as e.g. potassium-monopersulfate or peracetic acid, azine derivates, such as e.g. hexahydrotriazine, microbicide organic acids, such as e.g. apple acid, sorbic acid, salicylic acid or benzoic acid.

 The variety or the single microbicide agent/s are/is formulated into the product in an amount such that by using a conventional dosage of the product a disinfection of the medical
25 device during the processing in the processing apparatus is ensured. This may be determined first of all by using contaminated screws or pieces of rubber-tubes.

 During processing of medical devices the commonly used dosage regimen of the agents of the present invention are usually about 100 to 1000 ppm, preferably 200 to 600 ppm, most preferred 300 to 500 ppm, based on the entire bath, with the temperature of the bath being at
30 ambient temperature, preferably at elevated temperatures of up to 75 °C and with the time being maintained between 5 minutes and 10 minutes. With such a dosage regime about 50 to 400 ppm of non-ionic surfactants, 50 to 800 ppm of anorganic or organic acids and small amounts of

corrosion inhibitors, foam-reducing agents, perfume oils or dyes may be dosed.

Advantageously, the surfactants used in the product of the present invention are selected such that the cloud temperature of the agent in an aqueous medium is at the concentration of use at about the dosage temperature, at which the agent is added to the bath. This may be easily
5 determined by the person skilled in the art on the basis of his general knowledge.

For treating surfaces, such as floors in hospitals and the like, the concentration of the agent of the present invention in the washing fluid may be appropriately increased and is in the range of up to 1-2 %. Due to the low steam pressure of the agent high concentrations thereof in the washing fluid is not detrimental for the personnel, since essentially no transfer in the ambient
10 air occurs. Also a contact of diluted solutions with the skin is essentially not detrimental. The washing fluid for disinfecting and cleansing (degerminating cleansing) may easily be prepared by dosing the agent from a concentrated solution. Even applying a spray is possible, which may be used in particular for the treatment of athlete's foot. However, sprays may likewise be applied for the treatment of tables and the like.

The following examples illustrate the invention and are not to be construed to limit the invention. Examples 2 to 5 are for comparative purposes and show the superior properties of the products of the present invention during processing of devices.
15

Example 1

The disinfectant formulations 1 to 9, listed in the Table 1 as shown below, have been
20 prepared. In the formulations 2 to 5 no invert soap has been added.

Table 1
Disinfectant fomulations

formulation	1	2	3	4	5	6	7	8	9
decylisononyldimethyl-ammoniumchloride	3,00		4,00	8,00		2,00			
decylisononylmethyloxethyl-ammoniumpropionate								4,00	
didecyldimethylammoniumchloride		2,00			4,00				
dioctyldimethylammoniumchloride	2,00	3,00							4,00
ethylhexylisotridecyldimethyl-ammoniumchloride							5,00		
glutaraldehyde 50%									10,00
hexahydrotriazine						8,00			
citric acid		10,00	10,00	10,00	10,00			10,00	
acetic acid	5,00						5,00		5,00
1,2-propanediol	30,00	30,00	30,00	30,00	30,00	30,00	30,00	30,00	30,00
isotricetyl alcohol EO-PO	2,00	2,00	2,00	2,00	2,00		2,00	2,00	2,00
anti-foaming agent 3471		0,10		0,10	0,10		0,10	0,10	0,10

sodiumhydroxide solution 25%	18,00	36,00	36,00	36,00	36,00		18,00	36,00	10,00
benzotriazole	0,20	0,20	0,20	0,20	0,20		2,00	2,00	0,20
butindiole	0,50	0,50	0,50	0,50	0,50		0,50	0,50	0,50
water to 100									

The products are all clear and stable for at least one week even at elevated temperature of 50°C.

- 5 The capacity of the formulations to disintegrate blood has been examined on rubber tubes with wether blood that had been made coagulable and was heparinized. A thin blood layer has been deposited onto the tube pieces and left to dry for one hour.

The tube pieces were then immersed at a processing temperature of 60°C for 10 minutes in the disinfectant solution, taken after expiry of the time period and assessed after drying.

- 10 A relative scale of 1 to 5, taking water as a reference, has been drawn up.

Table II

	1	2	3	4	5	6	7	8	9	H ₂ O
meas.	2	5	3	3	5	1	2	2	2	1

As may be derived from Table II, above, the cleaning activity of the exemplary agents is improved as compared to the comparative formulations.

15 Example 2

The formulations shown in Table I have been examined for their efficacy in a Germ-Carrier-Assay using screws contaminated by *Streptococcus faecium* as the testing germ.

- 20 The assay has been performed at 50°C with the contamination being according to CEN. After incubation it was assessed, whether there were germs being capable to survive in the contamination on the screws after treatment or not. The number indicated shows the period of treatment required in minutes, after which no growth was detectable.

Table 3

	1	2	3	4	5	6	7	8	9	H ₂ O
min	6	10	7	7	10	5	5	5	6	20

- 25 The obvious superiority of the agent of the present invention as compared to the agents according to the prior art becomes evident.

Example 3

50 processing experiments have been carried out with different flexible endoscopes. During processing cleansing and disinfection has been carried out simultaneously in one bath. After processing the endoscopes have been analyzed for contaminations using swabs for preparing smears. The swabs were transferred to a culture medium which were incubated at 37°C for 24 h. The formulations according to the present invention did not show any residual contamination.

Claims

1. Use of invert soaps for disinfecting and cleaning surfaces of devices, characterized in that
5 the invert soap contains at least one branched alkyl chain, selected from nonyl, dodecyl and tridecyl.
2. The use according to claim 1, wherein the invert soap contains an additional long-chain
10 alkyl group as well as two short-chain alkyl groups.
3. The use according to claim 1, wherein the compound is isononyldecyldimethyl-
ammoniumchloride or ethylhexylisotridecyldimethylammoniumchloride.
4. The use according to any of the claims 1 to 3, wherein the surface to be treated is a
15 surface of medical devices.
5. The use according to claim 4, wherein the medical device is an endoscope or a dental
suction device.
- 20 6. The use according to any of the preceding claims, wherein the agent is used at a
temperature in the range of from 40 to 60 °C.

Summary


The present invention relates to agents for disinfecting and cleaning surfaces, wherein an invert
5 soap having at least one branched alkyl chain is utilized. In particular, the invention pertains to a
agent for disinfecting and cleaning surfaces, wherein the invert soap utilized has two short-chain
alkyl groups and two long-chain alkyl groups.

10

15

PCT

WELTORGANISATION FÜR GEISTIGES EIGENTUM
Internationales Büro



INTERNATIONALE ANMELDUNG VERÖFFENTLICHT NACH DEM VERTRAG ÜBER DIE
INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT)

(51) Internationale Patentklassifikation ⁷ : C11D 1/62, A61B 1/12, A61C 19/00		A1	(11) Internationale Veröffentlichungsnummer: WO 00/49118
		(43) Internationales Veröffentlichungsdatum:	24. August 2000 (24.08.00)
(21) Internationales Aktenzeichen: PCT/EP00/01334 (22) Internationales Anmeldedatum: 18. Februar 2000 (18.02.00) (30) Prioritätsdaten: 199 07 120.9 19. Februar 1999 (19.02.99) DE (71)(72) Anmelder und Erfinder: SCHUMACHER, Henning [DE/DE]; Thüringer Strasse 16, D-34212 Melsungen (DE). (74) Anwalt: STRAUS, Alexander; Becker, Kurig, Straus, Bavari- astrasse 7, D-80336 München (DE).		(81) Bestimmungsstaaten: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO Patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), europäisches Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Veröffentlicht Mit internationalem Recherchenbericht. Vor Ablauf der für Änderungen der Ansprüche zugelassenen Frist; Veröffentlichung wird wiederholt falls Änderungen eintreffen.	
(54) Title: <u>AGENTS FOR CLEANING AND DISINFECTING SURFACES</u>			
(54) Bezeichnung: MITTEL ZUR DESINFIZIERENDEN REINIGUNG VON OBERFLÄCHEN			
(57) Abstract The invention relates to agents for cleaning surfaces which also act as disinfectants. According to the invention, an invert soap with at least one branched alkyl chain is used. The invention relates to especially to agents of this type in which the invert soap used has two short-chained alkyl groups and two long-chained alkyl groups.			
(57) Zusammenfassung Die vorliegende Erfindung betrifft Mittel zur desinfizierenden Reinigung von Oberflächen, bei denen eine Invertseife mit mindestens einer verzweigten Alkylkette eingesetzt wird. Die Erfindung betrifft insbesondere Mittel zur desinfizierenden Reinigung von Oberflächen, wobei die eingesetzte Invertseife zwei kurzkettige Alkylgruppen und zwei langkettige Alkylgruppen aufweist.			

#10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In Re Application of:**

Henning SCHUMACHER

Group Art Unit: not yet known**Intl. Appln. No.:** PCT/EP00/01334**Examiner:** not yet assigned**Intl. Filing Date:** 18 February 2000**For:** AGENTS FOR CLEANING AND
DISINFECTING SURFACES**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a



Utility Patent



Design Patent

is sought on the invention, whose title appears above, the specification of which:



is attached hereto.

was filed on 18 February 2000 as International Application
No. PCT/EP00/01334.

said application having been amended on _____.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

- 2 -

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a-d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Priority Claimed (If X'd)	Country	Serial Number	Date Filed
<input checked="" type="checkbox"/>	Germany	199 07 120.9	19 February 1999
<input type="checkbox"/>			
<input type="checkbox"/>			
<input type="checkbox"/>			

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Date Filed	Patented/Pending/Abandoned

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Serial Number	Date Filed
---------------	------------

- 3 -

I hereby appoint the following persons of the firm of **WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP**, One Liberty Place - 46th Floor, Philadelphia, Pennsylvania 19103 as attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:


David A. CherryReg. No. 35,099

Reg. No. _____


Address all telephone calls and correspondence to:

David A. Cherry
WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
 One Liberty Place - 46th Floor
 Philadelphia PA 19103
 Telephone No.: (215) 568-3100
 Facsimile No.: (215) 568-3439

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00 Name: <u>Henning SCHUMACHER</u> <u>Dr. Schumacher GmbH</u>	 Signature Date of Signature: <u>02-05-03</u> Citizenship: <u>German</u>
Mailing Address: <u>Thüringer Strasse 16</u> <u>D-3412 Melsungen</u> <u>GERMANY</u> DEX	
City/State of Actual Residence: <u>Melsungen, GERMANY</u>	

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☒ **Scanned copy is best available.** *declaration have a line.*